(Q53139216)

11 May 2018

title

Cost-effectiveness of HER2 testing and trastuzumab therapy for metastatic breast cancer. (English)

1 reference

11 May 2018

cost-effectiveness analysis

main subject

1 reference

1 reference

4

1 reference

11 May 2018

author name string

Mathias Lidgren

series ordinal

1

1 reference

11 May 2018

Nils Wilking

series ordinal

2

1 reference

11 May 2018

Bengt Jönsson

series ordinal

3

1 reference

11 May 2018

publication date

1 January 2008

1 reference

11 May 2018

published in

Acta Oncologica

1 reference

11 May 2018

volume

47

1 reference

11 May 2018

issue

6

1 reference

11 May 2018

page(s)

1018-1028

1 reference

11 May 2018

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

cites work

1 reference

https://api.crossref.org/works/10.1080%2F02841860801901618

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860801901618

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860801901618

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860801901618

HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860801901618

A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model-based cost-effectiveness analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860801901618

Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860801901618

Resource use and costs associated with different states of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860801901618

Willingness to pay for a quality-adjusted life year: in search of a standard

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860801901618

Accounting for future costs in medical cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860801901618

The decision rules of cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860801901618

Incorporating future costs in medical cost-effectiveness analysis: implications for the cost-effectiveness of the treatment of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860801901618

10.1080/02841860801901618

21 January 2018

Identifiers

DOI

1 reference

11 May 2018

1 reference

11 May 2018